Pfizer Said to Have Approached Actavis About Deal

The transcript discusses the US government's efforts to prevent corporate inversions, focusing on Pfizer's attempts to acquire AstraZeneca. Despite new rules, companies like Pfizer find ways to navigate these regulations. The US faces challenges in stopping inversions without new legislation. Pfizer's previous hostile bid for AstraZeneca was unsuccessful, but they may attempt another bid after a cooling-off period, potentially influenced by the political climate post-US midterm elections.

What are 'hopscotch loans' and how do they relate to the US's efforts to stop inversions?

What might influence Pfizer's decision to make another bid for Astra Zeneca in the future?